Clinical outcome analysis of patients with autism spectrum disorder: analysis from the UK Medical Cannabis Registry

Introduction: Cannabis-based medicinal products (CBMPs) have been identified as a promising novel therapeutic for symptoms and comorbidities related to autism spectrum disorder (ASD). However, there is a paucity of clinical evidence of their efficacy and safety. Objective: This case series aims to assess changes to health-related quality of life and the incidence of adverse events in patients treated with CBMPs for associated symptoms of ASD enrolled on the UK Medical Cannabis Registry (UKMCR). Methods: Patients treated with CBMPs for ASD-related symptoms for a minimum of 1 month were identified from the UKMCR. Primary outcomes were changes in validated patient-reported outcome measures [Generalised Anxiety Disorder-7 (GAD-7), Single-Item Sleep Quality Scale (SQS), 5-level version of the EQ-5D (EQ-5D-5L) index values] at 1, 3 and 6 months compared with baseline. Adverse events were recorded and analysed. Statistical significance was determined by p < 0.050. Results: Seventy-four patients with ASD were included in the analysis. The mean age of participants was 32.7 (±11.6) years. There were significant improvements in general health-related quality of life and sleep as assessed by the EQ-5D-5L, SQS and GAD-7 at 1 and 3 months, with sustained changes in EQ-5D-5L and SQS at 6 months (p < 0.010). There were 180 (243.2%) adverse events reported by 14 (18.9%) participants. If present, adverse events were commonly mild (n = 58; 78.4%) or moderate (n = 81; 109.5%), rather than severe (n = 41; 55.4%). Conclusion: This study demonstrated an associated improvement in general health-related quality of life, and anxiety- and sleep-specific symptoms following initiation of treatment with CBMPs in patients with ASD. These findings, while promising, are limited by the confines of the study which lacks a control arm and is subject to attrition bias. Therefore, further evaluation is required with randomised controlled trials.

[1]  O. Aizpurua‐Olaizola,et al.  Sex-Dependent Prescription Patterns and Clinical Outcomes Associated With the Use of Two Oral Cannabis Formulations in the Multimodal Management of Chronic Pain Patients in Colombia , 2022, Frontiers in Pain Research.

[2]  M. Kawka,et al.  An Updated Analysis of Clinical Outcome Measures Across Patients From the UK Medical Cannabis Registry. , 2022, Cannabis and cannabinoid research.

[3]  M. Kawka,et al.  UK Medical Cannabis registry: an analysis of clinical outcomes of medicinal cannabis therapy for chronic pain conditions , 2021, Expert review of clinical pharmacology.

[4]  M. Kawka,et al.  UK Medical Cannabis Registry: an analysis of clinical outcomes of medicinal cannabis therapy for generalized anxiety disorder , 2021, Expert review of clinical pharmacology.

[5]  S. Baron-Cohen,et al.  Understanding the substance use of autistic adolescents and adults: a mixed-methods approach , 2021, The lancet. Psychiatry.

[6]  D. Hillman,et al.  Treating insomnia symptoms with medicinal cannabis: a randomized, crossover trial of the efficacy of a cannabinoid medicine compared with placebo , 2021, Sleep.

[7]  P. Diaz,et al.  Evaluation of Patient Reported Safety and Efficacy of Cannabis From a Survey of Medical Cannabis Patients in Canada , 2021, Frontiers in Public Health.

[8]  M. Weatherall,et al.  An initial analysis of the UK Medical Cannabis Registry: Outcomes analysis of first 129 patients , 2021, Neuropsychopharmacology reports.

[9]  S. Baron-Cohen,et al.  An investigation of the diet, exercise, sleep, BMI, and health outcomes of autistic adults , 2021, Molecular Autism.

[10]  V. Di Marzo.  The endocannabinoidome as a substrate for noneuphoric phytocannabinoid action and gut microbiome dysfunction in neuropsychiatric disorders
 , 2020, Dialogues in clinical neuroscience.

[11]  L. Fusar-Poli,et al.  Cannabinoids for People with ASD: A Systematic Review of Published and Ongoing Studies , 2020, Brain sciences.

[12]  I. McGregor,et al.  Medical cannabis use in the Australian community following introduction of legal access: the 2018–2019 Online Cross-Sectional Cannabis as Medicine Survey (CAMS-18) , 2020, Harm Reduction Journal.

[13]  Paula Case.  The NICE Guideline on Medicinal Cannabis: Keeping Pandora's Box Shut Tight? , 2020, Medical law review.

[14]  B. Arroll,et al.  Cannabidiol prescription in clinical practice: an audit on the first 400 patients in New Zealand , 2020, BJGP open.

[15]  D. Meiri,et al.  Medical cannabis and insomnia in older adults with chronic pain: a cross-sectional study , 2020, BMJ Supportive & Palliative Care.

[16]  C. Lord,et al.  Autism spectrum disorder , 2020, Nature Reviews Disease Primers.

[17]  L. Fusar-Poli,et al.  Prevalence and predictors of psychotropic medication use in adolescents and adults with autism spectrum disorder in Italy: A cross-sectional study , 2019, Psychiatry Research.

[18]  L. Fusar-Poli,et al.  Prevalence of Medical Comorbidities in Adults with Autism Spectrum Disorder , 2019, Journal of General Internal Medicine.

[19]  J. Tam,et al.  Lower circulating endocannabinoid levels in children with autism spectrum disorder , 2019, Molecular Autism.

[20]  V. Novack,et al.  Real life Experience of Medical Cannabis Treatment in Autism: Analysis of Safety and Efficacy , 2019, Scientific Reports.

[21]  Ellen Snyder,et al.  A New Single-Item Sleep Quality Scale: Results of Psychometric Evaluation in Patients With Chronic Primary Insomnia and Depression. , 2018, Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine.

[22]  K. Munir,et al.  Challenging behaviours at early adulthood in autism spectrum disorders: topography, risk factors and evolution , 2018, Journal of intellectual disability research : JIDR.

[23]  J. Gertsch.  The Intricate Influence of the Placebo Effect on Medical Cannabis and Cannabinoids , 2018, Medical Cannabis and Cannabinoids.

[24]  U. Kumar,et al.  Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System , 2018, International journal of molecular sciences.

[25]  J. Lagergren,et al.  The Charlson Comorbidity Index in Registry-based Research , 2017, Methods of Information in Medicine.

[26]  P. Santosh,et al.  Drug treatment of autism spectrum disorder and its comorbidities in children and adolescents , 2016, BJPsych Advances.

[27]  S. Sidney,et al.  The health status of adults on the autism spectrum , 2015, Autism : the international journal of research and practice.

[28]  Aubyn C. Stahmer,et al.  Naturalistic Developmental Behavioral Interventions: Empirically Validated Treatments for Autism Spectrum Disorder , 2015, Journal of Autism and Developmental Disorders.

[29]  T. Vos,et al.  The epidemiology and global burden of autism spectrum disorders , 2014, Psychological Medicine.

[30]  D. Finn,et al.  Alterations in the endocannabinoid system in the rat valproic acid model of autism , 2013, Behavioural Brain Research.

[31]  T. Kohlmann,et al.  Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[32]  E. Walker,et al.  Diagnostic and Statistical Manual of Mental Disorders , 2013 .

[33]  Zachary Warren,et al.  A Systematic Review of Medical Treatments for Children With Autism Spectrum Disorders , 2011, Pediatrics.

[34]  E. Murillo-Rodríguez.  The role of the CB1 receptor in the regulation of sleep , 2008, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[35]  B. Löwe,et al.  Validation and Standardization of the Generalized Anxiety Disorder Screener (GAD-7) in the General Population , 2008, Medical care.

[36]  S. Pocock,et al.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. , 2007, Preventive medicine.

[37]  Diane Vizine-Goetz,et al.  Spectrum , 2001 .

[38]  J. Rabe-Jabłońska,et al.  [Affective disorders in the fourth edition of the classification of mental disorders prepared by the American Psychiatric Association -- diagnostic and statistical manual of mental disorders]. , 1993, Psychiatria polska.

[39]  J. Bolton,et al.  Assessing the clinical significance of change scores recorded on subjective outcome measures. , 2004, Journal of manipulative and physiological therapeutics.